Goldman Sachs Group Inc. Acquires 644,428 Shares of Dynavax Technologies Co. (NASDAQ:DVAX)

Goldman Sachs Group Inc. raised its stake in shares of Dynavax Technologies Co. (NASDAQ:DVAX) by 21.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,597,139 shares of the biopharmaceutical company’s stock after acquiring an additional 644,428 shares during the quarter. Goldman Sachs Group Inc. owned approximately 2.75% of Dynavax Technologies worth $50,288,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. DekaBank Deutsche Girozentrale bought a new stake in Dynavax Technologies during the third quarter valued at about $33,000. Advisor Resource Council bought a new stake in shares of Dynavax Technologies in the 4th quarter valued at about $144,000. Rathbones Group PLC purchased a new position in shares of Dynavax Technologies in the 3rd quarter worth approximately $158,000. China Universal Asset Management Co. Ltd. bought a new position in shares of Dynavax Technologies during the 4th quarter worth approximately $209,000. Finally, AlphaMark Advisors LLC purchased a new stake in Dynavax Technologies during the fourth quarter valued at approximately $230,000. 96.96% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms have issued reports on DVAX. William Blair reaffirmed an “outperform” rating on shares of Dynavax Technologies in a report on Friday, February 23rd. HC Wainwright restated a “buy” rating and set a $29.00 target price on shares of Dynavax Technologies in a research note on Thursday, May 9th. Finally, StockNews.com cut Dynavax Technologies from a “buy” rating to a “hold” rating in a research note on Tuesday, May 28th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $25.33.

Insider Activity at Dynavax Technologies

In other Dynavax Technologies news, Director Francis Cano sold 3,615 shares of Dynavax Technologies stock in a transaction that occurred on Friday, May 31st. The shares were sold at an average price of $11.93, for a total transaction of $43,126.95. Following the completion of the sale, the director now directly owns 36,905 shares in the company, valued at approximately $440,276.65. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 2.98% of the stock is owned by insiders.

Dynavax Technologies Trading Down 0.5 %

NASDAQ:DVAX opened at $11.28 on Thursday. The company has a current ratio of 15.20, a quick ratio of 14.10 and a debt-to-equity ratio of 0.36. The firm has a fifty day simple moving average of $11.60 and a 200-day simple moving average of $12.58. Dynavax Technologies Co. has a 12 month low of $10.48 and a 12 month high of $15.15. The company has a market capitalization of $1.48 billion, a P/E ratio of 188.00 and a beta of 1.20.

Dynavax Technologies (NASDAQ:DVAX) last issued its quarterly earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.07) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.02). The firm had revenue of $50.79 million for the quarter, compared to analyst estimates of $51.98 million. Dynavax Technologies had a return on equity of 1.52% and a net margin of 3.91%. On average, equities research analysts anticipate that Dynavax Technologies Co. will post 0.12 earnings per share for the current year.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.